MNOV logo

MNOV MediciNova, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$1.29
-0.04 (-3.01%)

MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological…

Market Cap: $66.09Mwww.medicinova.com

Price

No data yet.

Social Signal Score

35
5d
—
30d
—
60d
34
4 mentions
—
90d
37
5 mentions
—
news: 5

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 0Sell 0Strong Sell 0
Avg price target$6+365.1%
Low $6Median $6High $6
Current Consensus

Revenue

$138.6K
$0.00$1.33M$2.67M$4.00M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.38
$-0.58–$-0.18
1 analysts
FY2026
$-0.24
$-0.26–$-0.21
1 analysts
FY2027
$-0.41
$-0.46–$-0.36
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Yuichi Iwaki
Sector
Healthcare
Industry
Biotechnology
Employees
6
Beta
0.61
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-4.01
www.medicinova.com